Artikel
Lizenziert
Nicht lizenziert
Erfordert eine Authentifizierung
Third Santorini conference pharmacogenomics workshop report: “Pharmacogenomics at the crossroads: what else than good science will be needed for the field to become part of Personalized Medicine?”
-
Adrián LLerena
Veröffentlicht/Copyright:
1. Juli 2007
Abstract
This workshop discussed the use of pharmacogenomics knowledge in clinical practice. It was organized in three sections: educational needs, definition of industry as a potential trigger, and regulatory aspects. Regarding pharmacogenomics education, it appears that this is truly lacking, except for patients, who are becoming increasingly educated thanks to the media. Regarding administrators, education is mainly a problem of cost. Indeed, even if cost-effective for society on the whole, pharmacogenomic tests will be expensive for hospitals. Physicians are facing an overabundance of information. They must be helped to bridge the gap between knowledge/research and clinical application. Collaboration between the pharmaceutical industry and the diagnostics industry could be one of the triggers. Moreover, there is a lack of qualification of this information, even though some guidelines are being produced. The Food and Drug Administration organizes workshops that often lead to publications on pharmacogenomic education, genomic data aims and development concepts, which can finally be translated into guidelines. Industry can contribute to pharmacogenomic development, not only through research, but also through marketing activities, which would promote the use of pharmacogenomics by physicians. Legal aspects were also considered in terms of the problem of availability and the degree of qualification of commercial drug tests on the market. The Innovative Medicine Initiative was also presented, which is a public-private partnership to create a biomedical research and development leader to benefit patients and society. Finally, a technical report from the Institute for Prospective Technological Studies on the socioeconomic impact of pharmacogenomics in the EU was presented.
Clin Chem Lab Med 2007;45:843–50.
Published Online: 2007-07-01
Published in Print: 2007-07-01
©2007 by Walter de Gruyter Berlin New York
Sie haben derzeit keinen Zugang zu diesem Inhalt.
Sie haben derzeit keinen Zugang zu diesem Inhalt.
Artikel in diesem Heft
- Pharmacogenomics and Personalized Medicine – a global reality check
- Pharmacogenomics and adverse drug reactions in diagnostic and clinical practice
- Impact of genetic polymorphisms on the risk of lipid disorders in patients on anti-HIV therapy
- Polymorphisms in genes involved in DNA repair and metabolism of xenobiotics in individual susceptibility to sporadic diffuse gastric cancer
- Effect of 13-cis-retinoic acid on the genetic expression profile of human umbilical vein endothelial cells (HUVECs) determined by microarray
- Association between T102C and A–1438G polymorphisms in the serotonin receptor 2A (5-HT2A) gene and schizophrenia: relevance for treatment with antipsychotic drugs
- A1166C polymorphism of the angiotensin AT1 receptor (AT1R) gene alters endothelial response to statin treatment
- Third Santorini conference pharmacogenomics workshop report: “Pharmacogenomics at the crossroads: what else than good science will be needed for the field to become part of Personalized Medicine?”
- On detecting interference from endogenous antibodies in immunoassays by doubling dilutions test
- High-sensitivity C-reactive protein concentration in patients with myocardial infarction-environmental factors, and polymorphisms in interleukin-10 and CD14 genes
- Tankyrase-1 mRNA expression in bladder cancer and paired urine sediment: preliminary experience
- A novel application of melting curves: utility of peak area calculation for relative methylation quantification
- Paraoxonase 1 gene polymorphisms in angiographically assessed coronary artery disease: evidence for gender interaction among Brazilians
- Tumor necrosis factor-α and oxidant status are essential participating factors in unexplained recurrent spontaneous abortions
- Paraoxonase and platelet-activating factor acetylhydrolase activities in lipoproteins of β-thalassemia/hemoglobin E patients
- Analysis of glomerular filtration rate, serum cystatin C levels, and renal resistive index values in cirrhosis patients
- Direct determination of selenium in human serum by inductively coupled plasma-collision cell-mass spectrometry
- Within-subject variation of plasma resistin levels over a 1-year period
- Global DNA methylation measured by liquid chromatography-tandem mass spectrometry: analytical technique, reference values and determinants in healthy subjects
- Values for free/total prostate-specific antigen ratio as a function of age: necessity of reference validation in a Turkish population
- Comparison of the Roche COBAS Amplicor™ Monitor, Roche COBAS Ampliprep™/COBAS Taqman™ and Abbott RealTime™ Test assays for quantification of hepatitis C virus and HIV RNA
- Genetic cystic fibrosis transmembrane regulator 4016insT D1152H compound heterozygosity and male infertility: an Italian case report
- Reference intervals for serum cystatin C in healthy Mexican adults
- Could standard ISO 15189 be useful for the conundrum of CA 19-9/GI Monitor measurement?
- Quality control strategy to verify day-to-day imprecision of length of blood sedimentation reaction measurements with the TEST-1 analyzer
- Applicability of α-fetoprotein-concanavalin A (AFP-ConA) binding to discriminate between germinal or hepatic origin of AFP in germ cell tumour patients during chemotherapy or follow-up
- Proposal of a candidate international conventional reference measurement procedure for free thyroxine in serum
- Balkan Clinical Laboratory Federation − past, present and future trends
Schlagwörter für diesen Artikel
education;
industry;
Personalized Medicine;
pharmacogenomics;
regulatory aspects
Artikel in diesem Heft
- Pharmacogenomics and Personalized Medicine – a global reality check
- Pharmacogenomics and adverse drug reactions in diagnostic and clinical practice
- Impact of genetic polymorphisms on the risk of lipid disorders in patients on anti-HIV therapy
- Polymorphisms in genes involved in DNA repair and metabolism of xenobiotics in individual susceptibility to sporadic diffuse gastric cancer
- Effect of 13-cis-retinoic acid on the genetic expression profile of human umbilical vein endothelial cells (HUVECs) determined by microarray
- Association between T102C and A–1438G polymorphisms in the serotonin receptor 2A (5-HT2A) gene and schizophrenia: relevance for treatment with antipsychotic drugs
- A1166C polymorphism of the angiotensin AT1 receptor (AT1R) gene alters endothelial response to statin treatment
- Third Santorini conference pharmacogenomics workshop report: “Pharmacogenomics at the crossroads: what else than good science will be needed for the field to become part of Personalized Medicine?”
- On detecting interference from endogenous antibodies in immunoassays by doubling dilutions test
- High-sensitivity C-reactive protein concentration in patients with myocardial infarction-environmental factors, and polymorphisms in interleukin-10 and CD14 genes
- Tankyrase-1 mRNA expression in bladder cancer and paired urine sediment: preliminary experience
- A novel application of melting curves: utility of peak area calculation for relative methylation quantification
- Paraoxonase 1 gene polymorphisms in angiographically assessed coronary artery disease: evidence for gender interaction among Brazilians
- Tumor necrosis factor-α and oxidant status are essential participating factors in unexplained recurrent spontaneous abortions
- Paraoxonase and platelet-activating factor acetylhydrolase activities in lipoproteins of β-thalassemia/hemoglobin E patients
- Analysis of glomerular filtration rate, serum cystatin C levels, and renal resistive index values in cirrhosis patients
- Direct determination of selenium in human serum by inductively coupled plasma-collision cell-mass spectrometry
- Within-subject variation of plasma resistin levels over a 1-year period
- Global DNA methylation measured by liquid chromatography-tandem mass spectrometry: analytical technique, reference values and determinants in healthy subjects
- Values for free/total prostate-specific antigen ratio as a function of age: necessity of reference validation in a Turkish population
- Comparison of the Roche COBAS Amplicor™ Monitor, Roche COBAS Ampliprep™/COBAS Taqman™ and Abbott RealTime™ Test assays for quantification of hepatitis C virus and HIV RNA
- Genetic cystic fibrosis transmembrane regulator 4016insT D1152H compound heterozygosity and male infertility: an Italian case report
- Reference intervals for serum cystatin C in healthy Mexican adults
- Could standard ISO 15189 be useful for the conundrum of CA 19-9/GI Monitor measurement?
- Quality control strategy to verify day-to-day imprecision of length of blood sedimentation reaction measurements with the TEST-1 analyzer
- Applicability of α-fetoprotein-concanavalin A (AFP-ConA) binding to discriminate between germinal or hepatic origin of AFP in germ cell tumour patients during chemotherapy or follow-up
- Proposal of a candidate international conventional reference measurement procedure for free thyroxine in serum
- Balkan Clinical Laboratory Federation − past, present and future trends
